Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
19 dec 2006 - 14:08
Statutaire naam
Crucell N.V.
Titel
Crucell and NIH Gain Approval and Move to Recruitment for Malaria Vaccine Clinical Study
Bericht
Leiden, The Netherlands, December 19, 2006 – Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that it has obtained regulatory and ethical approval to test the safety, tolerability and immunogenicity of its AdVac®-based malaria vaccine it is currently developing in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH). This opens the way for the imminent commencement of a Phase I clinical trial, with recruitment of volunteers underway.
Datum laatste update: 28 december 2025